摘要
Because the research paper of Alzheimer's disease(AD)new drug(GV-971)was suspected to be fraudulent,the author filed a lawsuit for infringement of reputation.A court in Shanghai rejected the lawsuit.Legal documents openly support academic disputes and criticism.The FDA's approval of the listing of a new AD drug(aducanumab)is also full of controversy,and some scholars suspect that there are problems with clinical data(of course there are scholars who support the listing).Falsification of scientific research and papers is not uncommon in China.In 2021,more than 400 people were publicly investigated for falsification of papers(these papers published in SCI journals).The reason for the prevalence of falsification was related to the promotion policy,evaluation system and economic interests.Academic fraud was a serious waste of funds and corrupted the academic atmosphere.And hinder the development of science and technology.In the past two years,the government has successively promulgated a series of scientific research and academic integrity norms,prohibiting the use of scientific research funds in international predatory journals,advocating the purification of the academic environment,and conducive to genuine innovative research.The court respects science,administration does not interfere with academics,and advocates peer review.The first-instance judgment may be a landmark event for China.
